📇 Rhumatologue · BRON CEDEX · (69) · Salarié

MME SARA BOCCALINI

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Plateau technique de référence
Hospices Civils de Lyon (HCL) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
18 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
144.6 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 BRON CEDEX (69)SalariéRPPS 10101457520

📊 Reconnaissance scientifique : 28/100📝 199 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Costs and healthcare utilisation due to respiratory syncytial virus disease in paediatric patients in Italy: a systematic review

Public health · 2024

📚 12 citations🎯 RCR 3.45Top 13% NIH🔓 Open Access

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy

Global & regional health technology assessment · 2025

📚 8 citations🎯 RCR 3.29🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Objectives: To describe the seasonal respiratory syncytial virus (RSV) burden in Italy considering the current prophylaxis strategy with palivizumab recommended only for high-risk infants (representing only 4.4% of an estimated birth cohort) and to evaluate the potential benefits of a new prophylaxis strategy targeting all infants with nirsevimab. Methods: A static decision analytic model previously used in the US was adapted to evaluate the RSV-related health and cost outcomes associated with nirsevimab versus standard of care (SoC) for the prevention of RSV medically attended lower respiratory tract infections (RSV-MA-LRTIs). Monthly probabilities of RSV infections, health events, mortality, and complications associated with RSV infections were obtained from the literature. Costs associated with each event were obtained using the available literature and through real-world data analysis of National Hospital Discharge Records. Results: For one RSV season, in the current SoC, the model estimated 216,100 RSV-MA-LRTIs, 15,121 associated complications, and 16 RSV-deaths–corresponding to an economic burden of approximately €50.5 million related to RSV-MA-LRTIs management, €10.9 million associated with potential complications due to RSV and €3 million in lost productivity due to RSV-deaths. Nirsevimab is expected to prevent 100,208 RSV-MA-LRTIs, 6,969 complications, and 6 deaths due to RSV infections, corresponding to an economic saving of about €23.3, €5, and €1.2 million, respectively. Conclusion: Nirsevimab is a new prophylaxis strategy that helps to protect all infants against RSV disease and could substantially reduce the clinical and economic burden of RSV in Italy in infants experiencing their first RSV season.

Respiratory Syncytial Virus associated hospitalisations in children up to 6 years of age in Italy: a systematic review

Annali di igiene : medicina preventiva e di comunita · 2025

📚 6 citations🎯 RCR 2.52

Cookies & analyse de trafic

MME SARA BOCCALINI

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (18) — classées par pathologie

Revue générale7

Transversal5

Revue / méta-analyse4

Pédiatrie3

Vraie vie / RWE3

Économie santé2

IRM ostéo-articulaire2

Case report / série1

Pharmacovigilance1

Datasets & protocoles partagés

Partager cette fiche